Clinical Efficacy of Transcatheter Closure of Patent Foramen Ovale with Positive Foaming Test
DOI:
https://doi.org/10.59958/hsf.7649Keywords:
congenital heart disease, patent foramen ovale, atrial septal defect, cryptogenic strokeAbstract
Background and Aims: To explore and evaluate the clinical therapeutic effect of interventional occlusion in the treatment of patent foramen ovale (PFO) with positive foaming test in the prevention and treatment of cryptogenic stroke (CS) and to provide clinical basis for individualized treatment of CS patients with PFO. Methods: A total of 151 patients who was admitted to Beijing Anzhen Nanchong Hospital Hospital from January 2019 to June 2021 were divided into two groups: drug therapy group (n = 63) and interventional occlusion + drug therapy group (n = 88). The general clinical data of the patients were collected by retrospective study, including sex, age, body weight, right to left shunt (RLS) magnitude, the degree of migraine before treatment, and telephone follow-up of all patients after treatment. Results: There was no significant difference in general clinical data (p > 0.05). In the interventional occlusion + drug therapy group, the stroke recurrence rate within 6th month after operation was significantly lower than that in the drug therapy group, and the difference was statistically significant (p < 0.05); The degree of migraine was lower than that in the drugs treatment group at the 3rd month after operation and the difference was statistically significant (p < 0.01); The degree of migraine at the 6th month was lower than that in the drug therapy group but the difference was not statistically significant (p > 0.05). The results of comprehensive generalized analysis showed that the risk of moderate or severe headache in the interventional occlusion + drug therapy group decreased by 40% (odds ratio [OR] = 0.60, p < 0.05). The degree of migraine in female patients was statistically lower after three and six months postoperatively (p < 0.05 and p = 0.01, respectively). Combined with generalized analysis, the risk of moderate or severe migraine in female patients was reduced by 55%. There were significant differences in the migraine before operation, migraine at the 3rd month and migraine at the 6th month in patients with three different kinds RLS grades (p < 0.01, p < 0.01, p < 0.05). Compared with the preoperative migraine and the migraine at the 3rd month, patients with RLS grade 3 had the most obvious migraine relief at the 6th month after operation than those with RLS grade 2. Conclusion: Compared with the drug therapy, interventional occlusion + drug therapy can reduce the risk of CS recurrence, improve the prognosis and significantly reduce the degree of migraine. Patients of different genders had different degrees of migraine, women had a lighter degree of migraine and a reduced risk of moderate or severe migraine, women benefited more after treatment. Patients with different RLS grades have different postoperative migraine relief. Patients with preoperative RLS grade 3 have the most obvious postoperative migraine relief and patients with preoperative RLS grade 3 benefit more after treatment.
References
Sadrameli SS, Gadhia RR, Kabir R, Volpi JJ. Patent Foramen Ovale in Cryptogenic Stroke and Migraine with Aura: Does Size Matter? Cureus. 2018; 10: e3213.
Giblett JP, Williams LK, Kyranis S, Shapiro LM, Calvert PA. Patent Foramen Ovale Closure: State of the Art. Interventional Cardiology. 2020; 15: e15.
Ho SY, McCarthy KP, Rigby ML. Morphological features pertinent to interventional closure of patent oval foramen. Journal of Interventional Cardiology. 2003; 16: 33–38.
Rana BS, Shapiro LM, McCarthy KP, Ho SY. Three-dimensional imaging of the atrial septum and patent foramen ovale anatomy: defining the morphological phenotypes of patent foramen ovale. European Journal of Echocardiography. 2010; 11: i19–i25.
Tian J, Chen X. PFO morphology for evaluation of c-TCD and c-TTE RLS grades. European Journal of Medical Research. 2022; 27: 228.
Safouris A, Kargiotis O, Psychogios K, Kalyvas P, Ikonomidis I, Drakopoulou M, et al. A Narrative and Critical Review of Randomized-Controlled Clinical Trials on Patent Foramen Ovale Closure for Reducing the Risk of Stroke Recurrence. Frontiers in Neurology. 2020; 11: 434.
Schnieder M, Siddiqui T, Karch A, Bähr M, Hasenfuss G, Liman J, et al. Clinical Relevance of Patent Foramen Ovale and Atrial Septum Aneurysm in Stroke: Findings of a Single-Center Cross-Sectional Study. European Neurology. 2017; 78: 264–269.
He Q, Zhang Y, Wang F, Li C, Guo R, Li X, et al. Impact of right-to-left shunt and transcatheter closure on the clinical features of migraine. The International Journal of Neuroscience. 2020; 130: 270–275.
Pristipino C, Sievert H, D'Ascenzo F, Louis Mas J, Meier B, Scacciatella P, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. European Heart Journal. 2019; 40: 3182–3195.
Zhao X, Deng Y. Research progress of patent foramina ovale and unexplained stroke. Chinese Journal of Cerebrovascular Diseases (electronic edition). 2020; 14: 163–166. (In Chinese)
Zito C, Dattilo G, Oreto G, Di Bella G, Lamari A, Iudicello R, et al. Patent foramen ovale: comparison among diagnostic strategies in cryptogenic stroke and migraine. Echocardiography. 2009; 26: 495–503.
Caputi L, Carriero MR, Falcone C, Parati E, Piotti P, Materazzo C, et al. Transcranial Doppler and transesophageal echocardiography: comparison of both techniques and prospective clinical relevance of transcranial Doppler in patent foramen ovale detection. Journal of Stroke and Cerebrovascular Diseases. 2009; 18: 343–348.
Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002; 105: 2625–2631.
Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. The New England Journal of Medicine. 2017; 377: 1011–1021.
Mir H, Siemieniuk RAC, Ge L, Foroutan F, Fralick M, Syed T, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open. 2018; 8: e023761.
Miranda B, Fonseca AC, Ferro JM. Patent foramen ovale and stroke. Journal of Neurology. 2018; 265: 1943–1949.
Sperlongano S, Giordano M, Ciccarelli G, Bassi G, Malvezzi Caracciolo D'Aquino M, Del Giudice C, et al. Advances in Percutaneous Patent Foramen Ovale Closure: From the Procedure to the Echocardiographic Guidance. Journal of Clinical Medicine. 2022; 11: 4001.
Gonnah AR, Bharadwaj MS, Nassar H, Abdelaziz HK, Roberts DH. Patent foramen ovale: diagnostic evaluation and the role of device closure. Clinical Medicine. 2022; 22: 441–448.
Shi F, Sha L, Li H, Tang Y, Huang L, Liu H, et al. Recent progress in patent foramen ovale and related neurological diseases: A narrative review. Frontiers in Neurology. 2023; 14: 1129062.
Turner ME, Bouhout I, Petit CJ, Kalfa D. Transcatheter Closure of Atrial and Ventricular Septal Defects: JACC Focus Seminar. Journal of the American College of Cardiology. 2022; 79: 2247–2258.
Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. Journal of the American College of Cardiology. 2006; 47: 440–445.
Messé SR, Gronseth G, Kent DM, Kizer JR, Homma S, Rosterman L, et al. Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2016; 87: 815–821.
Messé SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020; 94: 876–885.
Kavinsky CJ, Szerlip M, Goldsweig AM, Amin Z, Boudoulas KD, Carroll JD, et al. SCAI Guidelines for the Management of Patent Foramen Ovale. Journal of the Society for Cardiovascular Angiography & Interventions. 2022; 1: 100039.
Hoffman JIE, Kaplan S. The incidence of congenital heart disease. Journal of the American College of Cardiology. 2002; 39: 1890–1900.
Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. The New England Journal of Medicine. 2012; 366: 991–999.
Bronzetti G, D'Angelo C, Donti A, Salomone L, Giardini A, Maria Picchio F, et al. Role of atrial fibrillation after transcatheter closure of patent foramen ovale in patients with or without cryptogenic stroke. International Journal of Cardiology. 2011; 146: 17–21.
Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic Stroke: Research and Practice. Circulation Research. 2017; 120: 527–540.
Saver JL. CLINICAL PRACTICE. Cryptogenic Stroke. The New England Journal of Medicine. 2016; 374: 2065–2074.
Kent DM, Saver JL, Ruthazer R, Furlan AJ, Reisman M, Carroll JD, et al. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials. Stroke. 2020; 51: 3119–3123.
He D, Shi Q, Xu G, Hu Z, Li X, Li Q, et al. Clinical and infarction patterns of PFO-related cryptogenic strokes and a prediction model. Annals of Clinical and Translational Neurology. 2018; 5: 1323–1337.
Tobis JM. Patent foramen ovale: What cardiologists and neurologists need to know. Catheterization and Cardiovascular Interventions. 2019; 93: 1085–1086.
Windecker S, Meier B. Patent foramen ovale and atrial septal aneurysm: When and how should they be treated. ACC Current Journal Review. 2002; 3: 97–101.
Gu L, Wang Y, Shu H. Association between migraine and cognitive impairment. The Journal of Headache and Pain. 2022; 23: 88.
Liu K, Wang BZ, Hao Y, Song S, Pan M. The Correlation Between Migraine and Patent Foramen Ovale. Frontiers in Neurology. 2020; 11: 543485.
Qi Y, Zhang Y, Luo X, Cheng G, Du Y, Liu R, et al. Efficacy of patent foramen ovale closure for treating migraine: a prospective follow-up study. Journal of Investigative Medicine. 2021; 69: 7–12.
Del Sette M, Angeli S, Leandri M, Ferriero G, Bruzzone GL, Finocchi C, et al. Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovascular Diseases. 1998; 8: 327–330.
Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia. 2008; 28: 531–540.
Huo JY, Fu Y. Research progress of migraine related to patent foramina ovale. Chinese Journal of Neuropsychiatric Disorders. 2020; 46: 437–440. (In Chinese)
Hara H, Virmani R, Ladich E, Mackey-Bojack S, Titus J, Reisman M, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. Journal of the American College of Cardiology. 2005; 46: 1768–1776.
Elgendy AY, Saver JL, Amin Z, Boudoulas KD, Carroll JD, Elgendy IY, et al. Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke. JAMA Neurology. 2020; 77: 878–886.
Vizzari G, Pizzino F, Zwicke D, Tajik AJ, Carerj S, Di Bella G, et al. Patent foramen ovale: anatomical complexity and long-tunnel morphology related issues. American Journal of Cardiovascular Disease. 2021; 11: 316–329.
Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019; 394: 1145–1158.
Huang YX, Chen Y, Cao Y, Qiu YG, Zheng JY, Li TC. Thrombus straddling a patent foramen ovale and pulmonary embolism: A case report. World Journal of Clinical Cases. 2020; 8: 4902–4907.
Varotto L, Bregolin G, Paccanaro M, De Boni A, Bonanno C, Perini F. Network meta-analysis on patent foramen ovale: is a stroke or atrial fibrillation worse? Neurological Sciences. 2021; 42: 101–109.
Dia A, Cifu AS, Shah AP. Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA. JAMA. 2021; 325: 81–82.
Lanzone AM, Albiero R, Boldi E, Safari D, Serafin P, Lussardi G, et al. Clinical and echocardiographic outcomes after percutaneous closure of patent foramen ovale: a single center experience. Minerva Cardiology and Angiology. 2023; 71: 157–164.
Talafi Noghani M, Namdar H. Migraine associated with gastrointestinal disorders: A pathophysiological explanation. Medical Hypotheses. 2019; 125: 90–93.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38: 1–211.
Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019; 39: 687–710.
Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB. Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine. Headache. 2020; 60: 2003–2013.
Altamura C, Corbelli I, de Tommaso M, Di Lorenzo C, Di Lorenzo G, Di Renzo A, et al. Pathophysiological Bases of Comorbidity in Migraine. Frontiers in Human Neuroscience. 2021; 15: 640574.
Wang SB, Liu KD, Yang Y, Li YJ, Hu MY, Lin P, et al. Prevalence and extent of right-to-left shunt on contrast-enhanced transcranial Doppler in Chinese patients with migraine in a multicentre case-control study. Cephalalgia. 2018; 38: 690–696.
Hansen JM, Charles A. Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs. The Journal of Headache and Pain. 2019; 20: 96.
Cao W, Shen Y, Zhong J, Chen Z, Wang N, Yang J. The Patent Foramen Ovale and Migraine: Associated Mechanisms and Perspectives from MRI Evidence. Brain Sciences. 2022; 12: 941.
Sommer RJ, Robbins BT. Migraine and Patent Foramen Ovale: Is Platelet Hyperactivity the Underlying Mechanism? JACC. Basic to Translational Science. 2022; 7: 541–543.
Zhang QQ, Lu JJ, Yan MY, Hu XW, Qin YR, Wang DP, et al. The Efficacy of Percutaneous Patent Foramen Ovale Closure on Migraine: a Meta-Analysis of Randomized Controlled Trials and Observational Studies. BioMed Research International. 2021; 2021: 6643266.
Mojadidi MK, Kumar P, Mahmoud AN, Elgendy IY, Shapiro H, West B, et al. Pooled Analysis of PFO Occluder Device Trials in Patients With PFO and Migraine. Journal of the American College of Cardiology. 2021; 77: 667–676.
Mattle HP, Evers S, Hildick-Smith D, Becker WJ, Baumgartner H, Chataway J, et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. European Heart Journal. 2016; 37: 2029–2036.
Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, et al. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. Journal of the American College of Cardiology. 2017; 70: 2766–2774.
Liu D, Chen K, Gong J, Huang L, Dong X, Wan Q, et al. Right-to-left shunts in unexplained syncope: an age- and sex-matched case-control study. Quantitative Imaging in Medicine and Surgery. 2022; 12: 3592–3602.
Zhang YS, Jiang SL, Zhu XY. Chinese expert guidelines for the prevention of patent foramen ovale-associated stroke. Chinese Heart Journal. 2021; 33: 1–10. (In Chinese)
Published
How to Cite
Issue
Section
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
